New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 2 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 1 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.18.25

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

07.07.25

GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

Show More